Prognostic significance of lymphovascular infiltration in overall survival of gastric cancer patients after surgery with curative intent

Liangliang Wu¹, Yuexiang Liang², Chen Zhang³, Xiaona Wang¹, Xuewei Ding¹, Chongbiao Huang⁴, Han Liang¹

¹Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; ²Department of Gastrointestinal Oncology, the First Affiliated Hospital of Hainan Medical University, Haikou 570102, China; ³Nutritional Department, Tianjin Beichen Hospital, Tianjin 300090, China; ⁴Senior Ward, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

*These authors contributed equally to this work.

Correspondence to: Chongbiao Huang. Senior Ward, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Email: 1194460891@qq.com; Han Liang. Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Email: prof_lianghan@126.com.

Abstract

Objective: Lymphovascular infiltration (LVI) is frequently detected in gastric cancer (GC) specimens. Studies have revealed that GC patients with LVI have a poorer prognosis than those without LVI.

Methods: In total, 1,007 patients with curatively resected GC at Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital were retrospectively enrolled. The patients were categorized into two groups based on the LVI status: a positive group (PG; presence of LVI) and a negative group (NG; absence of LVI). The clinicopathological factors corrected with LVI and prognostic variables were analyzed. Additionally, a pathological lymphovascular-node (lvN) classification system was proposed to evaluate the superiority of its prognostic prediction of GC patients compared with that of the eighth edition of the N staging system.

Results: Two hundred twenty-four patients (22.2%) had LVI. The depth of invasion and lymph node metastasis were independently associated with the presence of LVI. GC patients with LVI demonstrated a significantly lower overall survival (OS) rate than those without LVI (42.8% vs. 68.9%, respectively; P<0.001). In multivariate analysis, LVI was identified as an independent prognostic factor for GC patients (hazard ratio: 1.370; 95% confidence interval: 1.094–1.717; P=0.006). Using strata analysis, significant prognostic differences between the groups were only observed in patients at stage I–IIIa or N0–2. The lvN classification was found to be more appropriate to predict the OS of GC patients after curative surgery than the pN staging system. The −2 log-likelihood of lvN classification (4,746.922) was smaller than the value of pN (4,765.196), and the difference was statistically significant (χ²=18.434, P<0.001).

Conclusions: The presence of LVI influences the OS of GC patients at stage I–IIIa or N0–2. LVI should be incorporated into the pN staging system to enhance the accuracy of the prognostic prediction of GC patients.

Keywords: Gastric carcinoma; lymphovascular infiltration; LVI; prognosis; risk factors

Submitted Dec 26, 2018. Accepted for publication Aug 02, 2019.
doi: 10.21147/j.issn.1000-9604.2019.05.08
View this article at: https://doi.org/10.21147/j.issn.1000-9604.2019.05.08
Introduction

A standard therapeutic strategy for gastric cancer (GC) by stage has been established in Japanese GC treatment guidelines. Radical gastrectomy with D2 lymph node dissection has become increasingly regarded as the standard surgical procedure for potentially curable T2–T4 tumors and cT1N+ tumors (1). Endoscopic submucosal dissection (ESD) is also indicated as a standard treatment for differentiated adenocarcinoma without ulcerative findings, in which the depth of invasion is clinically diagnosed as T1a and the diameter is ≤2 cm (1). Perioperative chemotherapy and chemoradiotherapy have been affirmed to further improve overall survival (OS) of advanced GC patients (2-4). However, even after curative surgery plus adjuvant therapy, the long-term outcome of GC remains poor. The main reason is that most patients have lymph node metastasis or micrometastasis at diagnosis. Lymphovascular infiltration (LVI), which is also referred to as blood vessel and lymphatic invasion, was reported to be a useful indicator of lymph node metastasis or distant metastasis (5,6). In Japanese GC treatment guidelines, the presence of LVI in endoscopically resected specimens is regarded as non-curative resection because of high incidence of lymph node metastasis, and gastrectomy with lymph node dissection should be performed subsequently as a remedy (1). The presence of LVI has been shown to be associated with a higher recurrence rate and poorer prognosis in several malignancies, including colorectal cancer, breast cancer, and non-small cell lung cancer (7-11). In hepatocellular carcinoma, LVI is included in the Barcelona Clinic Liver Cancer (BCLC) staging system, and the presence of LVI in the portal vein is classified as stage C (12). Regarding GC, LVI was frequently detected in the resected specimens, especially in advanced disease. However, its clinical significance has been rarely evaluated.

In this study, we retrospectively analyzed the outcomes of 1,007 GC patients who underwent surgery with curative intent. We aimed to evaluate the potential impact of LVI on long-term outcomes of GC patients after curative surgery and test the superiority of LvN classification for prognostic prediction in GC compared with N stage in the eighth edition of TNM staging system for GC.

Materials and methods

Patients

The Ethics Committee of Tianjin Medical University Cancer Institute and Hospital has reviewed and approved this study. A total of 1,508 patients with GC who underwent surgical resection at Tianjin Medical University Cancer Institute and Hospital between July 2011 and June 2013 were eligible for this study. The eligibility criteria for this study included the following: 1) patients with adenocarcinoma of the stomach; 2) patients who underwent gastrectomy with curative intent; 3) patients with stage I–IIIc disease; 4) patients with no history of gastrectomy or other malignancies; 5) patients with no history of neoadjuvant chemotherapy; 6) patients who received at least D1+ lymph node dissection; 7) patients with a total number of dissected lymph nodes greater than 16; 8) patients who were completely followed up; and 9) patients who did not die during the initial hospital stay or for 1 month after surgery. After excluding 4 patients with gastric neuroendocrine carcinoma, 1 patient with gastric squamous cell carcinoma, 20 patients with remnant GC, 14 patients with other malignant tumors, 38 patients who accepted neoadjuvant chemotherapy, 72 patients who received less than D1 lymph node dissection, 265 patients with lymph node retrieval less than 16, 7 patients who died within 1 month after surgery, 53 patients who were lost, and 27 patients with distant metastasis, ultimately, 1,007 patients were enrolled in this study.

Evaluation of clinicopathological variables and survival

Clinicopathological variables studied included 12 factors: sex, age at surgery, tumor location, Borrmann type, tumor size, histology, depth of invasion, lymph node metastasis, extranodal tumor deposits, LVI, preoperative carbohydrate antigen (CA)19-9 levels, and carcinoembryonic antigen (CEA) levels. Tumors were staged according to the 8th edition of the Union for International Cancer Control (UICC) TNM classification system, whereas lymphadenectomy and lymph node stations were defined according to the 3rd English edition of the Japanese Classification of Gastric Carcinoma and the 4th English edition of the Japanese Gastric Cancer Treatment Guidelines (13). The tumors were classified into two groups based on histology: differentiated type, including papillary, well or moderately differentiated adenocarcinoma; and undifferentiated type, including poorly differentiated or undifferentiated adenocarcinoma, signet ring cell carcinoma and mucinous carcinoma.

Incorporation of LVI into the eighth edition of UICC pN stage system

According to the prognostic impact of LVI on GC patients
with different pN stages, we established a new lympho-vascular-node (lvN) classification by incorporating LVI into the eighth edition of the UICC pN staging system. The lvN classification was defined as follows: lvN0, N0 stage without LVI; lvN1, N1 stage without LVI and N0 stage with LVI; lvN2, N2 stage without LVI; lvN3a, N3a stage regardless of LVI and N1−2 stages with LVI; lvN3b, N3b stage regardless of LVI. The differences in prognostic prediction between the eighth edition of the pN staging system and lvN classification system were directly compared.

Follow-up

The patients were followed up by an attending physician and research nurse at Department of Gastric Cancer, Tianjin Medical University Cancer Institute and Hospital. To increase the follow-up rate, methods such as telephone, message, correspondence and outpatient department visits were used together. The patients were followed up with every 3 months for up to 2 years after surgery, then every 6 months for up to 5 more years, and then once every year or until death. A physical examination, laboratory tests (including assessing CEA and CA19-9), and an abdominal ultrasound (US) were performed at each visit, while chest and abdominal computed tomography (CT) and endoscopy were obtained every 6 months or each year. The OS rate was calculated from the day of surgery until the time of death or final follow-up. The median follow-up was 53 (range: 2−72) months. The date of the final follow-up was July 30, 2018.

Statistical analysis

The categorical variables were analyzed using Chi-squared or Fisher’s exact test. Logistic regression analysis was used to identify the independent risk factors for the presence of LVI. The OS curves were calculated using the Kaplan-Meier method based on the length of time between the primary surgical treatment and final follow up or death. The log-rank test was used to assess significant differences between curves. Independent prognostic factors were identified by the Cox proportional hazards regression model. To compare the redefinition of the lvN classification with the eighth edition of the N staging system, the −2 log-likelihood between lvN classification and the N staging system was compared using analysis of variance, which was accomplished using R software (Version 3.4.3; R Foundation for Statistical Computing, Vienna, Austria). P<0.05 (bilateral) was considered statistically significant. Statistical analysis was performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA).

Results

Clinicopathological features and potential risk factors for presence of LVI

The 1,007 patients included 705 males (70.0%) and 302 females (30.0%). The age ranged from 19 to 86 years old, and the median age was 56 years old. Of the 1,007 GC patients, 383 underwent total gastrectomy, and 624 patients received subtotal gastrectomy. Regarding the extent of lymphadenectomy, D1+ lymphadenectomy was indicated for cT1N0 tumors and D2 lymphadenectomy for cN+ or cT2−T4 tumors. More extended lymphadenectomy than D2 was performed in patients with suspicious metastasis to No. 14v or No. 13 lymph node station. Thus, 176 patients underwent D2+ lymph node dissection, 764 patients had D2 dissection, and 67 patients had D1+ dissection. Seven hundred ninety-two patients received postoperative adjuvant chemotherapy with capecitabine, S-1, or 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX6), or capecitabine and oxaliplatin (XELOX) regimen.

Of the 1,007 GC patients who underwent gastrectomy, 224 (22.2%) patients had LVI. All the patients were categorized into 2 groups based on the LVI status: positive group (PG) and negative group (NG). Thus, 224 patients were assigned to PG, and 783 patients to NG. The clinicopathological factors were compared in Table 1. No significant differences were found in sex, age at surgery, and preoperative CA19-9 levels between the groups, while factors such as tumor location, Borrmann type, tumor size, histology, depth of invasion, lymph node metastasis, TNM stage, extranodal tumor deposits and preoperative CEA levels were correlated with the presence of LVI. In multivariate analysis, only depth of invasion [hazard ratio (HR): 1.270; 95% CI: 1.009−1.597; P=0.041] and lymph node metastasis (HR: 1.476; 95% CI: 1.286−1.694; P=0.001) were independently associated with the presence of LVI (Table 2).
| Clinicopathological features       | LVI [n (%)] | χ²  | P    |
|----------------------------------|-------------|-----|------|
|                                  | Absent      | Present      |
| Sex                              |             |               |
| Male                             | 555 (70.9)  | 150 (67.0)   | 1.273 | 0.253 |
| Female                           | 228 (29.1)  | 74 (33.0)    |       |       |
| Age at surgery (year)            |             |               |
| <70                              | 679 (86.7)  | 194 (86.6)   | 0.002 | 0.966 |
| ≥70                              | 104 (13.3)  | 30 (13.4)    |       |       |
| Tumor location                   |             |               |
| Lower                            | 337 (43.0)  | 72 (32.1)    | 11.980 | 0.007 |
| Middle                           | 185 (23.6)  | 57 (25.4)    |       |       |
| Upper                            | 128 (16.3)  | 38 (17.0)    |       |       |
| 2/3 or more                      | 133 (17.0)  | 57 (25.4)    |       |       |
| Borrmann type                    |             |               |
| 0                                | 149 (19.0)  | 8 (3.6)      | 38.338 | <0.001 |
| I                                | 38 (4.9)    | 7 (3.1)      |       |       |
| II                               | 78 (10.0)   | 19 (8.5)     |       |       |
| III                              | 475 (60.7)  | 169 (75.4)   |       |       |
| IV                               | 43 (5.5)    | 21 (9.4)     |       |       |
| Tumor size (cm)                  |             |               |
| <5                               | 450 (57.5)  | 91 (40.6)    | 19.882 | <0.001 |
| ≥5                               | 333 (42.5)  | 133 (59.4)   |       |       |
| Histology                        |             |               |
| Differentiated                   | 143 (18.3)  | 24 (10.7)    | 7.175 | 0.007 |
| Undifferentiated                 | 640 (81.7)  | 200 (89.3)   |       |       |
| Depth of invasion                |             |               |
| T1a                              | 91 (11.6)   | 3 (1.3)      | 46.846 | <0.001 |
| T1b                              | 61 (7.8)    | 5 (2.2)      |       |       |
| T2                               | 101 (12.9)  | 17 (7.6)     |       |       |
| T3                               | 31 (4.0)    | 6 (2.7)      |       |       |
| T4a                              | 475 (60.7)  | 180 (80.4)   |       |       |
| T4b                              | 24 (3.1)    | 13 (5.8)     |       |       |
| Lymph node metastasis            |             |               |
| N0                               | 407 (52.0)  | 52 (23.2)    | 89.659 | <0.001 |
| N1                               | 138 (17.6)  | 34 (15.2)    |       |       |
| N2                               | 120 (15.3)  | 54 (24.1)    |       |       |
| N3a                              | 89 (11.4)   | 52 (23.2)    |       |       |
| N3b                              | 29 (3.7)    | 32 (14.3)    |       |       |
| TNM stage                        |             |               |
| I                                | 217 (27.7)  | 14 (6.3)     | 91.709 | <0.001 |
| II                               | 230 (29.4)  | 51 (22.8)    |       |       |
| IIIa                             | 210 (26.8)  | 72 (32.1)    |       |       |

Table 1 (continued)
Survival analysis of all GC patients

Ten factors evaluated in univariate analysis had a significant effect on survival: age at surgery, tumor location, Borrmann type, tumor size, TNM stage, type of gastrectomy, extranodal tumor deposits, preoperative CA19-9 levels, CEA levels, and LVI status. GC patients with LVI had a significantly lower 5-year OS rate than those without LVI (5-year OS: 42.8% vs. 68.9%, respectively; \( P<0.001 \) (Figure 1A). In multivariate analysis, LVI (HR: 1.370 for PG; 95% CI: 1.094−1.717; \( P=0.006 \)) was found to be an independent prognostic factor for OS, as well as the following: age at surgery, Borrmann type IV, TNM stage and extranodal tumor deposits (Table 3).

Using strata analysis, the significant prognostic differences between the groups were only observed in GC patients at stage I−IIIa or N0−2 (Table 4). For patients at N0−2 stage (or with 0−6 lymph nodes metastasis), LVI had a significantly negative impact on OS, and the 5-year OS rates were 73.7% for those without LVI and 48.8% for those with LVI (\( P<0.001 \)) (Figure 1B).

Incorporation of LVI status into the eighth edition of UICC pN staging system

The OS of N0-stage patients with LVI was similar to that of N1-stage patients without LVI. The OS of N1- or N2-stage patients with LVI was equal to that of N3a-stage patients without LVI. In the N3a and N3b stages, no significant survival differences were found between patients with and without LVI (Figure 2). Based on these results, we incorporated LVI into the eighth edition of the UICC pN stage system and introduced the new pathological lvN classification (Table 5). Multivariate analysis was used to evaluate the value of pN stage (model 1) and lvN classification (model 2) to assess the prognosis of GC. Factors including

### Table 1 (continued)

| Clinicopathological features | LVI [n (%)] | \( \chi^2 \) | P    |
|-----------------------------|------------|-------------|------|
| Absent                      | Present    |             |      |
| IIIb                        | 94 (12.0)  | 50 (22.3)   |      |
| IIIc                        | 32 (4.1)   | 37 (16.5)   |      |
| Extranodal tumor deposits   |            |             |      |
| Absent                      | 585 (74.7) | 123 (54.9)  | 32.715 | <0.001 |
| Preset                      | 198 (25.3) | 101 (45.1)  |      |
| Preoperative CA19-9 levels  |            |             |      |
| Normal                      | 680 (86.8) | 186 (83.0)  | 2.099  | 0.147  |
| Elevated                    | 103 (13.2) | 38 (17.0)   |      |
| Preoperative CEA levels     |            |             |      |
| Normal                      | 682 (87.1) | 177 (79.0)  | 9.007  | 0.003  |
| Elevated                    | 101 (12.9) | 47 (21.0)   |      |

LVI, lymphovascular infiltration; CA19-9, carbohydrate antigen; CEA, carcinoembryonic antigen.

### Table 2 Multivariate analysis of risk factors for presence of LVI

| Clinicopathological features | HR    | 95% CI          | P    |
|------------------------------|-------|-----------------|------|
| Tumor size                   | 1.109 | 0.783−1.572     | 0.559|
| Borrmann type                | 1.101 | 0.854−1.420     | 0.458|
| Histology                    | 1.583 | 0.966−2.595     | 0.068|
| Lymph node metastasis        | 1.476 | 1.286−1.694     | <0.001|
| Tumor deposits               | 0.989 | 0.680−1.438     | 0.952|
| Preoperative CEA levels      | 1.202 | 0.796−1.813     | 0.382|
| Depth of invasion            | 1.270 | 1.009−1.597     | 0.041|
| Tumor location               | 1.060 | 0.920−1.221     | 0.418|

LVI, lymphovascular infiltration; CEA, carcinoembryonic antigen; HR, hazard ratio; 95% CI, 95% confident interval.
Table 3 Univariate and multivariate survival analysis of GC patients in the whole study series

| Characteristics       | n (%)   | 5-year OS (%) | Univariate analysis | Multivariate analysis |
|-----------------------|---------|---------------|---------------------|-----------------------|
|                       |         |               | $\chi^2$          | $p$                   | HR (95% CI)           | $p$ |
| Sex                   |         |               |                    |                       |                      |     |
| Male                  | 705 (70.0) | 64.6         | 1.680              | 0.195                 |                      |     |
| Female                | 302 (30.0) | 59.9         |                    |                       |                      |     |
| Age at surgery (year) |         |               | 9.434              | 0.002                 | 1 (ref)              |     |
| <70                   | 873 (86.7) | 64.9         |                    |                       |                      |     |
| ≥70                   | 134 (13.3) | 51.7         |                    |                       |                      |     |
| Tumor location        |         |               | 21.199             | <0.001                |                      |     |
| Lower one-third       | 409 (40.6) | 69.1         |                    |                       |                      |     |
| Middle one-third      | 242 (24.0) | 63.5         | 1.272              | 0.204                 | 0.878–1.844          |     |
| Upper one-third       | 166 (16.5) | 61.5         | 1.106              | 0.852                 | 0.710–1.327          |     |
| 2/3 or more           | 190 (18.9) | 51.3         | 1.160              | 0.466                 | 0.778–1.730          |     |
| Tumor size (cm)       |         |               | 41.781             | <0.001                |                      |     |
| <5                   | 541 (53.7) | 71.9         |                    |                       |                      |     |
| ≥5                   | 466 (46.3) | 53.1         | 1.013              | 0.929                 | 0.766–1.339          |     |
| Borrmann type         |         |               | 90.158             | <0.001                |                      |     |
| 0                    | 157 (15.6) | 90.4         | 1 (ref)            |                       |                      |     |
| I                    | 45 (4.5)   | 71.0         | 1.268              | 0.614                 | 0.504–3.193          |     |
| II                   | 97 (9.6)   | 68.9         | 2.004              | 0.083                 | 0.912–4.404          |     |
| III                  | 644 (64.0) | 57.9         | 1.589              | 0.240                 | 0.734–3.442          |     |
| IV                   | 64 (6.4)   | 34.4         | 2.683              | 0.021                 | 1.159–6.211          |     |
| Histology             |         |               | 2.427              | 0.119                 |                      |     |
| Differentiated        | 167 (16.6) | 68.2         |                    |                       |                      |     |
| Undifferentiated      | 840 (83.4) | 62.2         |                    |                       |                      |     |

Figure 1 Survival curves according to status of lymphovascular infiltration. (A) All patients ($p<0.001$); (B) Patients with 0–6 lymph node metastases ($p<0.001$).
age at surgery, depth of invasion, Borrmann type and tumor deposits were adjusted in multivariate analysis. The 5-year OS rates were 82.5%, 65.2%, 51.5%, 42.9%, and 26.2% in the lvN0, lvN1, lvN2, lvN3a and lvN3b stages, respectively ($\chi^2=196.855, P<0.001$). The 5-year OS rates were 80.1%, 61.1%, 49.9%, 43.3% and 26.2% in the pN0, pN1, pN2, pN3a and pN3b stages, respectively ($\chi^2=181.400, P<0.001$) (Table 6, Figure 3). The differences in the prognostic prediction between the eighth edition of the pN staging system and lvN classification system were directly compared (Table 6). The lvN classification (HR=1.642, 95% CI: 1.522–1.771, P<0.001) system was confirmed to be a more appropriate prognostic classification to predict the OS of GC patients after curative resection rather than the eighth edition of the pN classification (HR=1.605, 95% CI: 1.491–1.729; P<0.001). The −2 log-likelihood of the lvN stage was 4,746.922, which is smaller than the value of pN (4,765.196), and the difference was statistically significant ($\chi^2=18.434; P<0.001$).

**Discussion**

LVI is the presence of tumor cells within the blood or lymphatic vessels. LVI is a common pathological finding in cancer specimens and is regarded as an indicator of a poor prognosis for many types of cancer (7-11). Additionally, LVI is incorporated into the staging system of...
hepatocellular carcinoma because of its ability to predict the prognosis and recurrence (12,14). Regarding GC, the presence of LVI in endoscopically resected specimens is considered as a high-risk factor for lymph node metastasis according to the Japanese GC Treatment Guidelines (1). However, the value of LVI in specimens of gastrectomy has not been widely realized and no consensus has been reached. Although several studies have affirmed that LVI is independently associated with a poor survival of GC patients after surgery (15-21), the significance of LVI in GC remains uncertain, and its staging value is rarely assessed presently. In the present study, we found that the

### Table 4

| Tumor stage | 5-year OS (%) | χ² | P |
|-------------|---------------|----|---|
|             | LVI (-) | LVI (+) |    |
| N stage     |         |         |    |
| pN0         | 82.5    | 58.1    | 10.844 | 0.001 |
| pN1         | 67.2    | 35.8    | 13.529 | <0.001 |
| pN2         | 51.5    | 46.3    | 3.999  | 0.045  |
| pN3a        | 44.9    | 40.4    | 0.076  | 0.783  |
| pN3b        | 31.0    | 21.9    | 1.269  | 0.260  |
| TNM stage   |         |         |    |
| I           | 92.2    | 55.0    | 11.166 | 0.001  |
| II          | 73.4    | 58.2    | 4.457  | 0.035  |
| IIIa        | 57.0    | 44.3    | 4.293  | 0.038  |
| IIIb        | 43.6    | 40.0    | 0.001  | 0.990  |
| IIIc        | 31.3    | 21.6    | 1.759  | 0.185  |

| Strata survival analysis of GC patients according to tumor stage |
|---------------------------------------------------------------|
| Tumor stage | 5-year OS (%) | χ² | P |
|-------------|---------------|----|---|
|             | LVI (-) | LVI (+) |    |
| N stage     |         |         |    |
| pN0         | 82.5    | 58.1    | 10.844 | 0.001 |
| pN1         | 67.2    | 35.8    | 13.529 | <0.001 |
| pN2         | 51.5    | 46.3    | 3.999  | 0.045  |
| pN3a        | 44.9    | 40.4    | 0.076  | 0.783  |
| pN3b        | 31.0    | 21.9    | 1.269  | 0.260  |
| TNM stage   |         |         |    |
| I           | 92.2    | 55.0    | 11.166 | 0.001  |
| II          | 73.4    | 58.2    | 4.457  | 0.035  |
| IIIa        | 57.0    | 44.3    | 4.293  | 0.038  |
| IIIb        | 43.6    | 40.0    | 0.001  | 0.990  |
| IIIc        | 31.3    | 21.6    | 1.759  | 0.185  |

GC, gastric cancer; OS, overall survival; LVI, lymphovascular infiltration.

### Table 5

| LVI status | N0 | N1 | N2 | N3a | N3b |
|------------|----|----|----|-----|-----|
| Negative   | lvN0 | lvN1 | lvN2 | lvN3a | lvN3b |
| Positive   | lvN1 | lvN3a | lvN3a | lvN3a | lvN3b |

LVI, lymphovascular infiltration; GC, gastric cancer; lvN, lymphovascular-node.

Figure 2 Comparison of survival curves of patients with different N stages and lymphovascular infiltration (LVI) status. Overall survival (OS) of N0-stage patients with LVI was similar to that of N1-stage patients without LVI (P=0.581). OS of N1- or N2-stage patients with LVI was equal to that of N3a-stage patients without LVI (P values were 0.745 and 0.941, respectively).
depth of invasion and lymph node metastasis were independently correlated with the presence of LVI. LVI was identified as an independent prognostic factor for the whole study series. However, LVI did not affect the OS of GC patients at the pN3a and pN3b stages. After the incorporation of LVI into the pN stage, the new lvN
classification can better predict the prognosis for GC patients after curative surgery than the eighth edition of the pN staging system.

Presently, the major detection methods of LVI include haematoxylin-eosin (H&E) staining and immuno-histochemistry (IHC). In this retrospective study, the presence of LVI was detected in 22.2% of GC patients by H&E staining complemented by IHC with CD34. Li et al. reported that 35.2% of GC patients had presented with LVI as detected by H&E staining (18). However, a study by Dicken et al. indicated that LVI was detected in 59.6% of GC patients by IHC staining (19). According to previous studies, the positive rate of LVI in GC patients ranged from 10% to 60% (15-21). The different incidence rates of LVI may be due to different staining methods, number of examined samples, different criteria of LVI and different stages of the included patients. It was also reported that the accuracy of LVI diagnosis could be increased by using IHC with CD34 (a pan-endothelial marker) and D2-40 (a lymphatic endothelial) (22). Despite differences in the incidence of detection between the two methods, studies have confirmed that the presence of LVI, as detected by both H&E and IHC staining, is significantly correlated with the depth of invasion, lymph node metastasis and degree of malignancy (22-23). Our results were consistent with these findings, and multivariate logistic regression analysis identified that the depth of invasion and lymph node metastasis were independent risk factors correlated with the presence of LVI. Although the incidence of LVI is lower in early GC, the status of LVI determines the therapeutic strategy (24-28). ESD has been regarded as a standard curative therapy for selected T1a GC in the Japanese GC Treatment Guidelines (1). However, if LVI is presented in the specimen, additional gastrectomy plus lymph node dissection is needed to be performed (26,28) because the presence of LVI indicates a high incidence of lymph node metastasis. Actually, our data also supported this view. In the T1a stage GC patients, among the 3 patients with LVI, 2 also had lymph node metastasis; among the 91 patients without LVI, 86 were also absent of positive lymph nodes. The accuracy of the prediction of lymph node status by LVI was 93.6% [(86+2)/94x100%]. In our opinion, LVI is a reliable indicator of lymph node status in T1a GC, and patients with LVI are at a high risk of lymph node metastasis. More aggressive treatment, such as gastrectomy or postoperative chemotherapy, should be considered.

Regarding the prognostic value of LVI, previous studies had affirmed the positive influence of LVI on OS for various types of malignancies, including GC (7-12,15-21). Dicken et al. found that LVI is an independent predictor of survival in GC (19). Li et al. affirmed that the presence of vascular invasion is a risk factor for recurrence and is independently associated with the poor survival of non-metastatic GC (18). In the present study, GC patients with LVI demonstrated a significantly worse survival than those without LVI, and LVI was found to be an independent prognostic factor in multivariate analysis (HR: 1.370; 95% CI: 1.094-1.717; P=0.006). These results were consistent with previous studies and might indicate that LVI is a non-negligible factor for predicting the prognosis and determining the treatment strategies after surgery. The TNM classification of GC is the most important prognostic indicator and is considered a key clue for treatment. Nonetheless, it remains unclear whether LVI should be incorporated into the TNM staging system for GC. We found that the OS of N0-stage patients with LVI was similar to that of N1-stage patients without LVI. Additionally, no survival differences were observed among patients with LVI at N1, N2 and N3a disease, and the survival of N1–3a-stage patients with LVI was equal to that of N3a-stage patients without LVI. Based on these results, we incorporated the LVI status into the eighth edition of the UICC pN staging system, and then we proposed the new lvN classification system to evaluate the prognostic value of the pN stage and lvN classification in GC. We found that the lvN classification was a more appropriate prognostic classification to predict the OS of GC patients after curative resection than the eighth edition of the pN staging system. In our opinion, LVI contains some unique prognostic information that is not included in the TNM staging system and incorporating LVI into the new revision of the lvN classification for GC can better predict the prognosis and then determine treatment.

Conclusions

The presence of LVI indicates the aggressive characteristics of GC, such as deeper depth of invasion and more lymph nodes metastases. GC patients with LVI usually have a poorer prognosis, and survival of these patients at stage N0–2 is significantly worsened by LVI. Pathologists should be aware of this clinically important feature and carefully examine specimens from GC patients to determine the presence of LVI upon histological examination, and the LVI status should be recorded in the pathology report. Meanwhile, LVI should be considered in GC staging. GC patients with LVI should be closely
followed up and more seriously treated with gastrectomy or adjuvant chemotherapy.

Acknowledgements

This study was supported in part by grants from the Program of National Natural Science Foundation of China (No. 81572372); National Key Research and Development Program of Major Chronic Non-infectious Disease Prevention and Control Research (No. 2016YFC1303202); National Key Research and Development Program “Precision Medicine Research” Program (No. 2017YFC0908300); Application Foundation and Advanced Technology Program of Tianjin Municipal Science and Technology Commission (No. 15JCYBJC24800); and Scientific Research Project of Tianjin Municipal Education Commission (No. 2018KJ015).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
2. Katayama H, Tsuburaya A, Mizusawa J, et al. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer 2019.
3. Zhou ML, Yang W, Wang YQ, et al. Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses. Cancer Manag Res 2019;11:4855-70.
4. Xue K, Ying X, Bu Z, et al. Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II-III randomized trial. Chin J Cancer Res 2018;30:516-25.
5. Yamada T, Sugiyama H, Ochi D, et al. Risk factors for submucosal and lymphovascular invasion in gastric cancer looking indicative for endoscopic submucosal dissection. Gastric Cancer 2014;17:692-6.
6. Takizawa K, Ono H, Yamamoto Y, et al. Incidence of lymph node metastasis in intramucosal gastric cancer measuring 30 mm or less, with ulceration; mixed, predominantly differentiated-type histology; and no lymphovascular invasion: a multicenter retrospective study. Gastric Cancer 2016;19:1144-8.
7. Sun Q, Liu T, Liu P, et al. Perineural and lymphovascular invasion predicts for poor prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery. J Cancer 2019;10:2243-9.
8. Invernizzi M, Corti C, Lopez G, et al. Lymphovascular invasion and extranodal tumor extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up. BMC Cancer 2018;18:935.
9. Sung SY, Kwak YK, Lee SW, et al. Lymphovascular invasion increases the risk of nodal and distant recurrence in node-negative stage I-IIA non-small-cell lung cancer. Oncology 2018;95:156-62.
10. Yuk HD, Jeong CW, Kwak C, et al. Lymphovascular invasion have a similar prognostic value as lymph node involvement in patients undergoing radical cystectomy with urothelial carcinoma. Sci Rep 2018;8:15928.
11. Epstein JD, Kozak G, Fong ZV, et al. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. J Surg Oncol 2017;116:658-64.
12. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
13. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-12.
14. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-64.
15. Lee JH, Kim MG, Jung MS, et al. Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World J Surg 2015;39:732-9.
16. Kunisaki C, Makino H, Kimura J, et al. Impact of lymphovascular invasion in patients with stage I
gastric cancer. Surgery 2010;147:204-11.
17. Setälä LP, Kosma VM, Marin S, et al. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 1996;74:766-72.
18. Li P, He HQ, Zhu CM, et al. The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China. BMC Cancer 2015;15:370.
19. Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg 2006;243:64-73.
20. Zhang CD, Ning FL, Zeng XT, et al. Lymphovascular invasion as a predictor for lymph node metastasis and a prognostic factor in gastric cancer patients under 70 years of age: A retrospective analysis. Int J Surg 2018;53:214-20.
21. Lu J, Dai Y, Xie JW, et al. Combination of lymphovascular invasion and the AJCC TNM staging system improves prediction of prognosis in N0 stage gastric cancer: results from a high-volume institution. BMC Cancer 2019;19:216.
22. Gresta LT, Rodrigues-Júnior IA, de Castro LP, et al. Assessment of vascular invasion in gastric cancer: a comparative study. World J Gastroenterol 2013;19:3761-9.
23. Goto A, Nishikawa J, Hideura E, et al. Lymph node metastasis can be determined by just tumor depth and lymphovascular invasion in early gastric cancer patients after endoscopic submucosal dissection. Eur J Gastroenterol Hepatol 2017;29:1346-50.
24. Kim SJ, Choi CW, Kang DH, et al. Preoperative predictors of beyond endoscopic submucosal dissection indication or lymphovascular invasion in endoscopic resection for early gastric cancer. Surg Endosc 2018;32:2948-57.
25. Choi YY, Kim SJ, Choi CW, et al. Risk factors of submucosal or lymphovascular invasion in early gastric cancer <2 cm. Medicine (Baltimore) 2016;95:e3822.
26. Ono H, Yao K, Fujishiro M, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016;28:3-15.
27. Osumi H, Kawachi H, Murai K, et al. Risk stratification for lymph node metastasis using Epstein-Barr virus status in submucosal invasive (pT1) gastric cancer without lymphovascular invasion: a multicenter observational study. Gastric Cancer 2019.
28. Pyo JH, Lee H, Min YW, et al. Feasibility of endoscopic resection in early gastric cancer with lymphovascular invasion. Ann Surg Oncol 2019;26:449-55.

Cite this article as: Wu L, Liang Y, Zhang C, Wang X, Ding X, Huang C, Liang H. Prognostic significance of lymphovascular infiltration in overall survival of gastric cancer patients after surgery with curative intent. Chin J Cancer Res 2019;31(5):785-796. doi: 10.21147/j.issn.1000-9604.2019.05.08